Please take a moment to review the important CE information on this page.

Living with Advanced Non-Small Cell Lung Cancer
is no longer available for CME credit.

Accreditation

Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This activity is approved for 1.0 contact hour. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.

Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Contact NCCN at webcasts@nccn.org.

Program Overview
Lung cancer is the second most common cancer and leading cause of cancer-related deaths in both men and women. Although tobacco use is the strongest known risk factor for lung cancer, many people who never smoked also develop the disease. Regardless of how one developed lung cancer, treating the disease in the advanced stage faces numerous challenges for both physicians and patients as well as their families. This program will discuss those challenges and focus on choosing the best treatment regimen, decreasing treatment-related side effects, and selecting palliative therapies for patients with advanced non-small cell lung cancer.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Describe new systemic treatment regimens for patients with advanced non-small cell lung cancer
• List criteria for selecting the best treatment regimen for select patients with advanced non-small cell lung cancer
• Identify strategies to help decrease treatment-related side effects of systemic therapy for non-small cell lung cancer
• Describe decision-making paradigms for selecting palliative therapies in patients with advanced non-small cell lung cancer

Target Audience
Physicians, nurses, and other clinical professionals who manage patients with cancer.

Faculty Disclosure Information
All faculty participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's and ANCC's Standards for Commercial Support.

Acknowledgement of Commercial Support
Supported by educational grants from Eli Lilly and Company and Genentech.